Roche Holding AG’s (ROG.VX) pipeline has regained its health. After the company was hit by a series of research setbacks last year that prompted the Swiss pharmaceutical giant to launch a multi-billion Swiss franc revamp and cut around 5,000 jobs, Roche’s medical pipeline looks promising again after recent research success, analysts say.
